Latest News and Press Releases

NEW YORK and LONDON, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...

NEW YORK and LONDON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...

NEW YORK and LONDON, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...

Completion of enrollment into COBALT, the Phase II PNH trial of Coversin™ NEW YORK and LONDON, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company...

NEW YORK and LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to...

NEW YORK and LONDON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive...

NEW YORK and LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX) is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive...

NEW YORK and LONDON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson, Chief...

NEW YORK and LONDON, June 23, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European...

NEW YORK and LONDON, April 27, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison...